289PDLucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. (23rd October 2018) - Hui, R; Pearson, A; Cortes Castan, J; Campbell, C; Poirot, C; Azim, H A; Fumagalli, D; Lambertini, M; Daly, F; Arahmani, A; Perez-Garcia, J; Aftimos, P G; et al.